Safety and efficacy of CMX001 as salvage therapy for severe adenovirus infections in immunocompromised patients.

@article{Florescu2012SafetyAE,
  title={Safety and efficacy of CMX001 as salvage therapy for severe adenovirus infections in immunocompromised patients.},
  author={D F Florescu and Steven A Pergam and Michael Neely and Fang Qiu and Christine P Johnston and SingSing Way and J B Vander Sande and David M Lewinsohn and Judith A. Guzman-Cottrill and Michael L. Graham and Genovefa Papanicolaou and Joanne Kurtzberg and J. Brian Rigdon and Wendy P Painter and Herv{\'e} Momm{\'e}ja-Marin and Randall Lanier and Maggie Anderson and Charles Michael van der Horst},
  journal={Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation},
  year={2012},
  volume={18 5},
  pages={731-8}
}
No therapeutic agent has yet been established as the definitive therapy for adenovirus infections. We describe the clinical experience of 13 immunocompromised patients who received CMX001 (hexadecyloxypropyl cidofovir), an orally bioavailable lipid conjugate of cidofovir, for adenovirus disease. We retrospectively analyzed 13 patients with adenovirus disease and viremia treated with CMX001; data were available for ≥ 4 weeks after initiation of CMX001 therapy. Virologic response (VR) was defined… CONTINUE READING